Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Stetler-Stevenson Website

Maryalice Stetler-Stevenson, M.D., Ph.D.

Selected Publications

1)  Korde N, Carlsten M, Lee M, Minter A, Tan E, Kwok M, Manasanch E, Bhutani M, Tageja N, Roschewski M, Zingone A, Costello R, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan R, Tembhare P, Yuan C, Stetler-Stevenson M, Trepel J, Childs R, Landgren O.
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
Haematologica. [Epub ahead of print], 2014.
[Journal]
2)  Wilson WH, Bromberg JE, Stetler-Stevenson M, Steinberg SM, Martin-Martin L, Muñiz C, Sancho J, Caballero MD, Davidis MA, Brooimans RA, Sanchez-Gonzalez B, Salar A, González-Barca E, Ribera JM, Shovlin M, Filie A, Dunleavy K, Mehrling T, Spina M, Orfao A.
Detection and utcome of occult leptomeningeal disease in diffuselarge B-cell lymphoma and Burkitt lymphoma.
Haematologica. [Epub ahead of print], 2014.
[Journal]
3)  Tembhare PR, Yuan CM, Venzon D, Braylan R, Korde N, Manasanch E, Zuchlinsky D, Calvo K, Kurlander R, Bhutani M, Tageja N, Maric I, Mulquin M, Roschewski M, Kwok M, Liewehr D, Landgren O, Stetler-Stevenson M.
Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.
Leuk. Res. 38: 371-6, 2014.
[Journal]
4)  Roschewski M, Stetler-Stevenson M, Yuan C, Mailankody S, Korde N, Landgren O.
Minimal residual disease: what are the minimum requirements?.
J. Clin. Oncol. 32: 475-6, 2014.
[Journal]
5)  Stetler-Stevenson M.
Monoclonal B-cell lymphocytosis in donors.
Blood. 123: 1281-2, 2014.
[Journal]
6)  Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ.
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
Blood. 121: 1165-74, 2013.
[Journal]
7)  Degheidy HA, Gadalla SM, Farooqui MZ, Abbasi F, Arthur DC, Bauer SR, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE.
Bcl-2 level as a biomarker for 13q14 deletion in CLL.
Cytometry B Clin Cytom. 84: 237-47, 2013.
[Journal]
8)  Burotto M, Stetler-Stevenson M, Arons E, Zhou H, Wilson W, Kreitman RJ.
Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.
Clin. Cancer Res. 19: 6313-21, 2013.
[Journal]
9)  Klion AD, Mejia R, Cowen EW, Dowdell KC, Dunleavy K, Fahle GA, Holland-Thomas N, Maric I, Pittaluga S, Raffeld M, Santos C, Stetler-Stevenson M, Krogmann T, Shatzer AN, Turk SP, Yin Y, Xi L, Prussin C, Cohen JI.
Chronic active Epstein-Barr virus infection: a novel cause of lymphocytic variant hypereosinophilic syndrome.
Blood. 121: 2364-6, 2013.
[Journal]
10)  Kreitman RJ, Wilson W, Calvo KR, Arons E, Roth L, Sapolsky J, Zhou H, Raffeld M, Stetler-Stevenson M.
Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.
Clin. Cancer Res. 19: 6873-81, 2013.
[Journal]
11)  Shao H, Calvo KR, Grönborg M, Tembhare PR, Kreitman RJ, Stetler-Stevenson M, Yuan CM.
Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria.
Leuk. Res. 37: 401-9, 2013.
[Journal]
12)  Manasanch EE, Braylan R, Stetler-Stevenson M, Yuan C, Gounden V, Korde N, Tageja N, Bhutani M, Calvo K, Maric I, Roschewski M, Staudt LM, Landgren O.
Lack of MYD88 L265P in non-IgM lymphoplasmacytic lymphoma.
Leuk. Lymphoma. [Epub ahead of print], 2013.
[Journal]
13)  Flanders A, Stetler-Stevenson M, Landgren O.
Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity.
Blood. 122: 1088-9, 2013.
[Journal]
14)  Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Maric I, Calvo KR, Braylan R, Stetler-Stevenson M, Yuan C, Tembhare P, Zingone A, Costello R, Roschewski MJ, Landgren O.
Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study.
Leuk. Lymphoma. 54: 2215-8, 2013.
[Journal]
15)  Tembhare PR, Marti G, Wiestner A, Degheidy H, Farooqui M, Kreitman RJ, Jasper GA, Yuan CM, Liewehr D, Venzon D, Stetler-Stevenson M.
Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia.
Am. J. Clin. Pathol. 140: 813-8, 2013.
[Journal]
16)  Shaffer BC, Modric M, Stetler-Stevenson M, Arthur DC, Steinberg SM, Liewehr DJ, Fowler DH, Gale RP, Bishop MR, Pavletic SZ.
Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia.
Exp. Hematol. 41: 772-8, 2013.
[Journal]
17)  Greig B, Stetler-Stevenson M, Lea J.
Stabilization media increases recovery in paucicellular cerebrospinal fluid specimens submitted for flow cytometry testing.
Cytometry B Clin Cytom. 86: 135-8, 2013.
[Journal]
18)  Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA.
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
Blood. 119: 2709-20, 2012.
[Journal]
19)  Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, Kreitman RJ.
Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.
Blood. 119: 3330-2, 2012.
[Journal]
20)  Tembhare P, Yuan CM, Xi L, Marti G, Raffeld M, Stetler-Stevenson M.
Case study interpretation--Portland: Case 1. Hairy cell leukemia with CLL-like monoclonal B lymphocytosis.
Cytometry B Clin Cytom. 82: 177-9, 2012.
[Journal]
21)  Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE.
Combined normal donor and CLL: Single tube ZAP-70 analysis.
Cytometry B Clin Cytom. 82: 67-77, 2012.
[Journal]
22)  Hardy NM, Fellowes V, Rose JJ, Odom J, Pittaluga S, Steinberg SM, Blacklock-Schuver B, Avila DN, Memon S, Kurlander RJ, Khuu HM, Stetler-Stevenson M, Mena E, Dwyer AJ, Levine BL, June CH, Reshef R, Vonderheide RH, Gress RE, Fowler DH, Hakim FT, Bishop MR.
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.
Blood. 119: 2956-9, 2012.
[Journal]
23)  Tembhare P, Yuan CM, Morris JC, Janik JE, Filie AC, Stetler-Stevenson M.
Flow cytometric immunophenotypic assessment of T-cell clonality by vβ repertoire analysis in fine-needle aspirates and cerebrospinal fluid.
Am. J. Clin. Pathol. 137: 220-6, 2012.
[Journal]
24)  Song JY, Filie AC, Venzon D, Stetler-Stevenson M, Yuan CM.
Flow cytometry increases the sensitivity of detection of leukemia and lymphoma cells in bronchoalveolar lavage specimens.
Cytometry B Clin Cytom. 82: 305-12, 2012.
[Journal]
25)  Shah NN, Bacher U, Fry T, Calvo KR, Stetler-Stevenson M, Arthur DC, Kurlander R, Baird K, Wise B, Giralt S, Bishop M, Hardy NM, Wayne AS.
Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: Diagnostic and therapeutic challenges.
Am J Hematol. 87: 916-22, 2012.
[Journal]
26)  Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I.
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia.
J. Clin. Oncol. 30: 1822-8, 2012.
[Journal]
27)  Pérez-Galán P, Mora-Jensen H, Weniger MA, Shaffer AL, Rizzatti EG, Chapman CM, Mo CC, Stennett LS, Rader C, Liu P, Raghavachari N, Stetler-Stevenson M, Yuan C, Pittaluga S, Maric I, Dunleavy KM, Wilson WH, Staudt LM, Wiestner A.
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.
Blood. 117: 542-52, 2011.
[Journal]
28)  Venkataraman G, Aguhar C, Kreitman RJ, Yuan CM, Stetler-Stevenson M.
Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders.
Am. J. Clin. Pathol. 136: 625-30, 2011.
[Journal]
29)  Stetler-Stevenson M, Tembhare PR.
Diagnosis of hairy cell leukemia by flow cytometry.
Leuk. Lymphoma. 52 Suppl 2: 11-3, 2011.
[Journal]
30)  Arons E, Roth L, Sapolsky J, Suntum T, Stetler-Stevenson M, Kreitman RJ.
Evidence of canonical somatic hypermutation in hairy cell leukemia.
Blood. 117: 4844-51, 2011.
[Journal]
31)  Tembhare P, Yuan CM, Xi L, Morris JC, Liewehr D, Venzon D, Janik JE, Raffeld M, Stetler-Stevenson M.
Flow cytometric immunophenotypic assessment of T-cell clonality by Vβ repertoire analysis: detection of T-cell clonality at diagnosis and monitoring of minimal residual disease following therapy.
Am. J. Clin. Pathol. 135: 890-900, 2011.
[Journal]
32)  Calvo KR, McCoy CS, Stetler-Stevenson M.
Flow cytometry immunophenotyping of hematolymphoid neoplasia.
Methods Mol. Biol. 699: 295-316, 2011.
[Journal]
33)  Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wiestner A, Stetler-Stevenson MA, Marti GE.
Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlation.
Cytometry. Part B, Clinical Cytom. 80: 309-17, 2011.
[Journal]
34)  Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE.
Methodological comparison of two anti-ZAP-70 antibodies.
Cytometry. Part B, Clinical Cytom. 80: 300-8, 2011.
[Journal]
35)  Calvo KR, Vinh DC, Maric I, Wang W, Noel P, Stetler-Stevenson M, Arthur DC, Raffeld M, Dutra A, Pak E, Myung K, Hsu AP, Hickstein DD, Pittaluga S, Holland SM.
Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications.
Haematologica. 96: 1221-5, 2011.
[Journal]
36)  Marti GE, Stetler-Stevenson M, Grant ND, White T, Figg WD, Tohnya T, Jaffe ES, Dunleavy K, Janik JE, Steinberg SM, Wilson WH.
Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia.
Leuk Lymphoma. 52: 2284-92, 2011.
[Journal]
37)  Kreitman RJ, Arons E, Stetler-Stevenson M, Fitzgerald DJ, Wilson WH, Pastan I.
Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.
Leuk. Lymphoma. 52 Suppl 2: 82-6, 2011.
[Journal]
38)  Kreitman RJ, Arons E, Stetler-Stevenson M, Miller KB.
Response of hairy cell leukemia to bendamustine.
Leuk. Lymphoma. 52: 1153-6, 2011.
[Journal]
39)  Yuan CM, Stetler-Stevenson M.
Role of flow cytometry of peripheral blood and bone marrow aspirates in early myeloma.
Semin. Hematol. 48: 32-8, 2011.
[Journal]
40)  Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, Gibellini F, Njuguna N, Lee E, Stennett L, Raghavachari N, Liu P, McCoy JP, Raffeld M, Stetler-Stevenson M, Yuan C, Sherry R, Arthur DC, Maric I, White T, Marti GE, Munson P, Wilson WH, Wiestner A.
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.
Blood. 117: 563-74, 2011.
[Journal]
41)  Jasper GA, Arun I, Venzon D, Kreitman RJ, Wayne AS, Yuan CM, Marti GE, Stetler-Stevenson M.
Variables affecting the quantitation of CD22 in neoplastic B cells.
Cytometry B Clin Cytom. 80: 83-90, 2011.
[Journal]
42)  Yeh S, Weichel ED, Faia LJ, Albini TA, Wroblewski KK, Stetler-Stevenson M, Ruiz P, Sen HN, Chan CC, Nussenblatt RB.
25-Gauge transconjunctival sutureless vitrectomy for the diagnosis of intraocular lymphoma.
Br J Ophthalmol. 94: 633-8, 2010.
[Journal]
43)  Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, Stetler-Stevenson M, Fitzgerald DJ, Pastan I.
Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
Clin. Cancer Res. 16: 1894-903, 2010.
[Journal]
44)  Mussai F, Campana D, Bhojwani D, Stetler-Stevenson M, Steinberg SM, Wayne AS, Pastan I.
Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia.
Br. J. Haematol. 150: 352-8, 2010.
[Journal]
45)  Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DN, Lanier BJ, Morgan RA, Rosenberg SA.
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically-engineered to recognize CD19.
Blood. 116: 4099-102, 2010.
[Journal]
46)  Morisot S, Wayne AS, Bohana-Kashtan O, Kaplan IM, Gocke CD, Hildreth R, Stetler-Stevenson M, Walker RL, Davis S, Meltzer PS, Wheelan SJ, Brown P, Jones RJ, Shultz LD, Civin CI.
High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias.
Leukemia. 24: 1859-66, 2010.
[Journal]
47)  Shao H, Yuan CM, Xi L, Raffeld M, Morris JC, Janik JE, Stetler-Stevenson M.
Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma.
Am. J. Clin. Pathol. 133: 592-601, 2010.
[Journal]
48)  Sportès C, Babb RR, Krumlauf MC, Hakim FT, Steinberg SM, Chow CK, Brown MR, Fleisher TA, Noel P, Maric I, Stetler-Stevenson M, Engel J, Buffet R, Morre M, Amato RJ, Pecora A, Mackall CL, Gress RE.
Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy.
Clin. Cancer Res. 16: 727-35, 2010.
[Journal]
49)  Wang L, Abbasi F, Jasper GA, Kreitman RJ, Liewehr DJ, Marti GE, Stetler-Stevenson M.
Variables in the quantification of CD4 in normals and Hairy cell leukemia patients.
Cytometry B Clin Cytom. 80B: 51-57, 2010.
[Journal]
50)  Arun I, Wulu JA, Janik JE, Jasper GA, Yuan CM, Venzon D, Stetler-Stevenson M.
Visual inspection versus quantitative flow cytometry to detect aberrant CD2 expression in malignant T cells.
Cytometry B Clin Cytom. 78: 169-75, 2010.
[Journal]
51)  O'Mahony D, Morris JC, Stetler-Stevenson M, Matthews H, Brown MR, Fleisher T, Pittaluga S, Raffeld M, Albert PS, Reitsma D, Kaucic K, Hammershaimb L, Waldmann TA, Janik JE.
EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies.
Clin. Cancer Res. 15: 2514-22, 2009.
[Journal]
52)  Stetler-Stevenson M.
Flow cytometric immunophenotyping: emerging as an important diagnostic tool in the evaluation of cytopenic patients.
Leuk. Res. 33: 1020-1, 2009.
[Journal]
53)  Stetler-Stevenson M, Yuan CM.
Myelodysplastic syndromes: the role of flow cytometry in diagnosis and prognosis.
Int J Lab Hematol. 31: 479-83, 2009.
[Journal]
54)  Rizzo K, Stetler-Stevenson M, Wilson W, Yuan CM.
Novel CD19 expression in a peripheral T cell lymphoma: A flow cytometry case report with morphologic correlation.
Cytometry B Clin Cytom. 76: 142-9, 2009.
[Journal]
55)  Jiang L, Abati AD, Wilson W, Stetler-Stevenson M, Yuan C.
Persistent non-neoplastic gammadelta-T cells in cerebrospinal fluid of a patient with hepatosplenic (gammadelta) T cell lymphoma: a case report with 6 years of flow cytometry follow-up.
Int J Clin Exp Pathol. 3: 110-6, 2009.
[Journal]
56)  Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE.
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
J. Clin. Oncol. 27: 5410-7, 2009.
[Journal]
57)  Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I.
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.
J. Clin. Oncol. 27: 2983-90, 2009.
[Journal]
58)  Jiang L, Yuan CM, Hubacheck J, Janik JE, Wilson W, Morris JC, Jasper GA, Stetler-Stevenson M.
Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
Br. J. Haematol. 145: 173-9, 2009.
[Journal]
59)  Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ.
VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.
Blood. 114: 4687-95, 2009.
[Journal]
60)  Du X, Nagata S, Ise T, Stetler-Stevenson M, Pastan I.
FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins.
Blood. 111: 338-43, 2008.
[Journal]
61)  Kraan J, Gratama JW, Haioun C, Orfao A, Plonquet A, Porwit A, Quijano S, Stetler-Stevenson M, Subira D, Wilson W.
Flow cytometric immunophenotyping of cerebrospinal fluid.
Current Protoc Cytom. Chapter 6: Unit 6.25, 2008.
[Journal]
62)  Ahmad E, Steinberg SM, Goldin L, Hess CJ, Caporaso N, Kreitman RJ, Wiestner A, Wilson W, White T, Marti G, Stetler-Stevenson M.
Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemia.
Cytometry B Clin Cytom. 74: 221-6, 2008.
[Journal]
63)  Arons E, Suntum T, Margulies I, Yuan C, Stetler-Stevenson M, Kreitman RJ.
PRAME expression in hairy cell leukemia.
Leuk. Res. 32: 1400-6, 2008.
[Journal]
64)  Matsushita K, Margulies I, Onda M, Nagata S, Stetler-Stevenson M, Kreitman RJ.
Soluble CD22 as a tumor marker for hairy cell leukemia.
Blood. 112: 2272-7, 2008.
[Journal]
65)  Kim YS, Seo DW, Kong SK, Lee JH, Lee ES, Stetler-Stevenson M, Stetler-Stevenson WG.
TIMP1 induces CD44 expression and the activation and nuclear translocation of SHP1 during the late centrocyte/post-germinal center B cell differentiation.
Cancer Lett. 269: 37-45, 2008.
[Journal]
66)  Stetler-Stevenson M, Davis B, Wood B, Braylan R.
2006 Bethesda International Consensus Conference on Flow Cytometric Immunophenotyping of Hematolymphoid Neoplasia.
Cytometry B Clin Cytom. 72B: S3, 2007.
[Journal]
67)  Davis BH, Holden JT, Bene MC, Borowitz MJ, Braylan RC, Cornfield D, Gorczyca W, Lee R, Maiese R, Orfao A, Wells D, Wood BL, Stetler-Stevenson M.
2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: Medical indications.
Cytometry B Clin Cytom. 72B: S5-S13, 2007.
[Journal]
68)  Abbasi F, Longo NS, Lipsky PE, Raveche E, Schleinitz TA, Stetler-Stevenson M, Caporaso N, Marti G.
B-cell repertoire and clonal analysis in unaffected first degree relatives in familial chronic lymphocytic leukaemia kindred.
Br. J. Haematol. 139: 820-3, 2007.
[Journal]
69)  Hardy NM, Grady C, Pentz R, Stetler-Stevenson M, Raffeld M, Fontaine LS, Babb R, Bishop MR, Caporaso N, Marti GE.
Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation.
Br. J. Haematol. 139: 824-31, 2007.
[Journal]
70)  Ise T, Nagata S, Kreitman RJ, Wilson WH, Wayne AS, Stetler-Stevenson M, Bishop MR, Scheinberg DA, Rassenti L, Kipps TJ, Kyle RA, Jelinek DF, Pastan I.
Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma.
Leukemia. 21: 169-74, 2007.
[Journal]
71)  Arons E, Suntum T, Sunshine J, Stetler-Stevenson M, Kreitman RJ.
Immunoglobulin light chain repertoire in hairy cell leukemia.
Leuk. Res. 31: 1231-6, 2007.
[Journal]
72)  Arons E, Sorbara L, Raffeld M, Stetler-Stevenson M, Steinberg SM, Liewehr DJ, Pastan I, Kreitman RJ.
Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy.
Cancer Immunol. Immunother. 55: 1100-10, 2006.
[Journal]
73)  Schinstine M, Filie AC, Wilson W, Stetler-Stevenson M, Abati A.
Detection of malignant hematopoietic cells in cerebral spinal fluid previously diagnosed as atypical or suspicious.
Cancer. 108: 157-62, 2006.
[Journal]
74)  Rosenberg SA, Sportès C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, Stetler-Stevenson M, Morton KE, Mavroukakis SA, Morre M, Buffet R, Mackall CL, Gress RE.
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells.
J. Immunother. 29: 313-9, 2006.
[Journal]
75)  Arons E, Margulies I, Sorbara L, Raffeld M, Stetler-Stevenson M, Pastan I, Kreitman RJ.
Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction.
Clin. Cancer Res. 12: 2804-11, 2006.
[Journal]
76)  Ahmad E, Kingma DW, Jaffe ES, Schrager JA, Janik J, Wilson W, Stetler-Stevenson M.
Flow cytometric immunophenotypic profiles of mature gamma delta T-cell malignancies involving peripheral blood and bone marrow.
Cytometry B Clin Cytom. 67: 6-12, 2005.
[Journal]
77)  Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, Dunleavy K, Jaffe ES, Abati A, Stetler-Stevenson M, Wilson WH.
High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology.
Blood. 105: 496-502, 2005.
[Journal]
78)  Aurran-Schleinitz T, Telford W, Perfetto S, Caporaso N, Wilson W, Stetler-Stevenson MA, Zenger VE, Abbasi F, Marti GE.
Identification of a new monoclonal B-cell subset in unaffected first-degree relatives in familial chronic lymphocytic leukemia.
Leukemia. 19: 2339-41, 2005.
[Journal]
79)  Fogarty PF, Stetler-Stevenson M, Pereira A, Dunbar CE.
Large granular lymphocytic proliferation-associated cyclic thrombocytopenia.
Am J Hematol. 79: 334-336, 2005.
[Journal]
80)  Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, Pastan I.
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.
J. Clin. Oncol. 23: 6719-29, 2005.
[Journal]
81)  Lamb LS, Neuberg R, Welsh J, Best R, Stetler-Stevenson M, Sorrell A.
T-cell lymphoblastic leukemia/lymphoma syndrome with eosinophilia and acute myeloid leukemia.
Cytometry B Clin Cytom. 65: 37-41, 2005.
[Journal]
82)  Guedez L, Martinez A, Zhao S, Vivero A, Pittaluga S, Stetler-Stevenson M, Raffeld M, Stetler-Stevenson WG.
Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.
Blood. 105: 1660-8, 2005.
[Journal]
83)  Neelapu SS, Kwak LW, Kobrin CB, Reynolds CW, Janik JE, Dunleavy K, White T, Harvey L, Pennington R, Stetler-Stevenson M, Jaffe ES, Steinberg SM, Gress R, Hakim F, Wilson WH.
Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.
Nat. Med. 11: 986-91, 2005.
[Journal]
84)  Lunning MA, Zenger VE, Dreyfuss R, Stetler-Stevenson M, Rick ME, White TA, Wilson WH, Marti GE.
Albumin enhanced morphometric image analysis in CLL.
Cytometry B Clin Cytom. 57: 7-14, 2004.
[Journal]
85)  Haviernik P, Lahoda C, Bradley HL, Hawley TS, Ramezani A, Hawley RG, Stetler-Stevenson M, Stetler-Stevenson WG, Bunting KD.
Tissue inhibitor of matrix metalloproteinase-1 overexpression in M1 myeloblasts impairs IL-6-induced differentiation.
Oncogene. 23: 9212-9, 2004.
[Journal]
86)  Marti GE, Carter P, Abbasi F, Washington GC, Jain N, Zenger VE, Ishibe N, Goldin L, Fontaine L, Weissman N, Sgambati M, Fauget G, Bertin P, Vogt RF, Slade B, Noguchi PD, Stetler-Stevenson MA, Caporaso N.
B-cell monoclonal lymphocytosis and B-cell abnormalities in the setting of familial B-cell chronic lymphocytic leukemia.
Cytometry. 52B: 1-12, 2003.
[Journal]
87)  Marti GE, Vogt RF, Stetler-Stevenson M.
Clinical quantitative flow cytometry:.
Cytometry. 55B: 59, 2003.
[Journal]
88)  Stetler-Stevenson M.
Flow cytometry in lymphoma diagnosis and prognosis: useful?.
Best Pract Res Clin Haematol. 16: 583-97, 2003.
[Journal]
89)  Sausville JE, Salloum RG, Sorbara L, Kingma DW, Raffeld M, Kreitman RJ, Imus PD, Venzon D, Stetler-Stevenson M.
Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene.
Am J Clin Pathol. 119: 213-7, 2003.
[Journal]
90)  Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM.
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
Blood. 101: 4944-51, 2003.
[Journal]
91)  Dahmoush L, Hijazi Y, Barnes E, Stetler-Stevenson M, Abati A.
Adult T-cell leukemia/lymphoma: a cytopathologic, immunocytochemical, and flow cytometric study.
Cancer. 96: 110-6, 2002.
[Journal]
92)  Kingma DW, Imus P, Xie XY, Jasper G, Sorbara L, Stewart C, Stetler-Stevenson M.
CD2 is expressed by a subpopulation of normal B cells and is frequently present in mature B-cell neoplasms.
Cytometry. 50: 243-8, 2002.
[Journal]
93)  Lunning MA, Stetler-Stevenson M, Silberstein PT, Zenger V, Marti GE.
Spontaneous (pathological) splenic rupture in a blastic variant of mantle cell lymphoma: a case report and literature review.
Clin Lymphoma. 3: 117-20, 2002.
[Journal]
94)  Saunthararajah Y, Molldrem JL, Rivera M, Williams A, Stetler-Stevenson M, Sorbara L, Young NS, Barrett JA.
Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features.
Br J Haematol. 112: 195-200, 2001.
[Journal]
95)  Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, Venzon D, Rick ME.
Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome.
Blood. 98: 979-87, 2001.
[Journal]
96)  Wersto RP, Chrest FJ, Leary JF, Morris C, Stetler-Stevenson MA, Gabrielson E.
Doublet discrimination in DNA cell-cycle analysis.
Cytometry. 46: 296-306, 2001.
[Journal]
97)  Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I.
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.
N Engl J Med. 345: 241-7, 2001.
[Journal]
98)  Stetler-Stevenson M, Braylan RC.
Flow cytometric analysis of lymphomas and lymphoproliferative disorders.
Semin Hematol. 38: 111-23, 2001.
[Journal]
99)  Marti GE, Stetler-Stevenson M, Bleesing JJ, Fleisher TA.
Introduction to flow cytometry.
Semin Hematol. 38: 93-9, 2001.
[Journal]
100)  Guedez L, McMarlin AJ, Kingma DW, Bennett TA, Stetler-Stevenson M, Stetler-Stevenson WG.
Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis.
Am J Pathol. 158: 1207-15, 2001.
[Journal]
101)  Guedez L, Mansoor A, Birkedal-Hansen B, Lim MS, Fukushima P, Venzon D, Stetler-Stevenson WG, Stetler-Stevenson M.
Tissue inhibitor of metalloproteinases 1 regulation of interleukin-10 in B-cell differentiation and lymphomagenesis.
Blood. 97: 1796-802, 2001.
[Journal]
102)  Zhou Q, Wulfkuhle J, Ouatas T, Fukushima P, Stetler-Stevenson M, Miller FR, Steeg PS.
Cyclin D1 overexpression in a model of human breast premalignancy: preferential stimulation of anchorage-independent but not anchorage-dependent growth is associated with increased cdk2 activity.
Breast Cancer Res Treat. 59: 27-39, 2000.
[Journal]
103)  Kreitman RJ, Margulies I, Stetler-Stevenson M, Wang QC, FitzGerald DJ, Pastan I.
Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Clin Cancer Res. 6: 1476-87, 2000.
[Journal]
104)  Xie XY, Sorbara L, Kreitman RJ, Fukushima PI, Kingma DW, Stetler-Stevenson M.
Development of lymphoproliferative disorder of granular lymphocytes in association with hairy cell leukemia.
Leuk Lymphoma. 37: 97-104, 2000.
[Journal]
105)  Xie XY, Filie AC, Jasper GA, Fukushima PI, Stetler-Stevenson M.
Diagnosis of unexpected acute myeloid leukemia and chronic lymphocytic leukemia: a case report demonstrating the perils of restricted panels in flow cytometric immunophenotyping.
Cytometry. 42: 114-7, 2000.
[Journal]
106)  Robbins DH, Margulies I, Stetler-Stevenson M, Kreitman RJ.
Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2).
Clin Cancer Res. 6: 693-700, 2000.
[Journal]
107)  Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, Waldmann TA, Pastan I.
Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
J Clin Oncol. 18: 1622-36, 2000.
[Journal]
108)  Zhou Q, Fukushima P, DeGraff W, Mitchell JB, Stetler Stevenson M, Ashkenazi A, Steeg PS.
Radiation and the Apo2L/TRAIL apoptotic pathway preferentially inhibit the colonization of premalignant human breast cells overexpressing cyclin D1.
Cancer Res. 60: 2611-5, 2000.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 4/15/2014.